

Cameroon has successfully stopped mass drug administration (MDA) for lymphatic filariasis in the country following interruption of transmission of the causative parasite in all 142 endemic districts as of FY22 (October 2021 – September 2022).

91% of districts have stopped MDA after trachoma impact surveys indicated the elimination threshold of trachomatous inflammation—follicular (TF) of less than 5% among children ages 1-9 years and have maintained the elimination threshold for at least 2 years in the absence of MDA as of FY19 (October 2018 – September 2019).

The National program has validated the onchocerciasis national strategic plan (2020-2024). The plan defines the strategic priorities and the mechanisms necessary to achieving interruption of transmission by 2025 in all the endemic foci.
Standard Disease-Specific Indicators as of FY20
FY20 is October 2019 through September 2020

of ever-endemic districts have stopped MDA as of FY20
(i.e. have passed stop MDA survey, TAS1 (First Transmission Assessment Survey))*
* MDA has stopped for LF in all districts in Cameroon except one
No ever-endemic districts in post-surveillance phase as of FY20
(i.e. have passed last surveillance survey, TAS3 (third Transmission Assessment Survey))
of persons no longer at risk as of FY20 among those who were ever at risk

of ever-endemic districts have stopped MDA as of FY20
(i.e. have passed stop MDA survey, TIS (Trachoma Impact Survey))*
*Cameroon is ever endemic but not treated through USAID; treated with other, non-USAID support
of ever-endemic districts in post-surveillance phase as of FY20
(i.e. have passed surveillance survey, TSS (Trachoma Surveillance Survey))
of persons no longer at risk as of FY20 among those who were ever at risk

of ever endemic districts have been treated at least once as of FY20

of ever endemic districts have been treated at least once as of FY20
